Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

ObjectiveCurrent treatment agents for HCC are mostly immune checkpoint inhibitors (ICIs) plus bevacizumab and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PFS) discourage their frequent use. The development...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Ningning Yan, Ziheng Zhang, Sanxing Guo, Shujing Shen, Xingya Li
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Frontiers Media S.A. 2023-05-01
Sraith:Frontiers in Medicine
Ábhair:
Rochtain ar líne:https://www.frontiersin.org/articles/10.3389/fmed.2023.1130012/full

Míreanna comhchosúla